Cargando…

Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice

BACKGROUND: Trovafloxacin is a broad-spectrum antibiotic, recently identified as an inhibitor of pannexin-1 (Panx1) channels. Panx1 channels are important conduits for the adenosine triphosphate (ATP) release from live and dying cells that enhances the inflammatory response of immune cells. Elevated...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Charu, Seo, Joon Ho, Ramachandran, Jayalakshmi, Loh, Ji Meng, Calderon, Frances, Contreras, Jorge E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812039/
https://www.ncbi.nlm.nih.gov/pubmed/29439712
http://dx.doi.org/10.1186/s12974-018-1069-9
_version_ 1783299963477819392
author Garg, Charu
Seo, Joon Ho
Ramachandran, Jayalakshmi
Loh, Ji Meng
Calderon, Frances
Contreras, Jorge E.
author_facet Garg, Charu
Seo, Joon Ho
Ramachandran, Jayalakshmi
Loh, Ji Meng
Calderon, Frances
Contreras, Jorge E.
author_sort Garg, Charu
collection PubMed
description BACKGROUND: Trovafloxacin is a broad-spectrum antibiotic, recently identified as an inhibitor of pannexin-1 (Panx1) channels. Panx1 channels are important conduits for the adenosine triphosphate (ATP) release from live and dying cells that enhances the inflammatory response of immune cells. Elevated extracellular levels ATP released upon injury activate purinergic pathways in inflammatory cells that promote migration, proliferation, phagocytosis, and apoptotic signals. Here, we tested whether trovafloxacin administration attenuates the neuroinflammatory response and improves outcomes after brain trauma. METHODS: The murine controlled cortical impact (CCI) model was used to determine whether in vivo delivery of trovafloxacin has anti-inflammatory and neuroprotective actions after brain trauma. Locomotor deficit was assessed using the rotarod test. Levels of tissue damage markers and inflammation were measured using western blot, qPCR, and immunofluorescence. In vitro assays were used to evaluate whether trovafloxacin blocks ATP release and cell migration in a chemotactic-stimulated microglia cell line. RESULTS: Trovafloxacin treatment of CCI-injured mice significantly reduced tissue damage markers and improved locomotor deficits. In addition, trovafloxacin treatment significantly reduced mRNA levels of several pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), which correlates with an overall reduction in the accumulation of inflammatory cell types (neutrophils, microglia/macrophages, and astroglia) at the injury zone. To determine whether trovafloxacin exerted these effects by direct action on immune cells, we evaluated its effect on ATP release and cell migration using a chemotactic-stimulated microglial cell line. We found that trovafloxacin significantly inhibited both ATP release and migration of these cells. CONCLUSION: Our results show that trovafloxacin administration has pronounced anti-inflammatory and neuroprotective effects following brain injury. These findings lay the foundation for future studies to directly test a role for Panx1 channels in pathological inflammation following brain trauma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-018-1069-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5812039
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58120392018-02-15 Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice Garg, Charu Seo, Joon Ho Ramachandran, Jayalakshmi Loh, Ji Meng Calderon, Frances Contreras, Jorge E. J Neuroinflammation Research BACKGROUND: Trovafloxacin is a broad-spectrum antibiotic, recently identified as an inhibitor of pannexin-1 (Panx1) channels. Panx1 channels are important conduits for the adenosine triphosphate (ATP) release from live and dying cells that enhances the inflammatory response of immune cells. Elevated extracellular levels ATP released upon injury activate purinergic pathways in inflammatory cells that promote migration, proliferation, phagocytosis, and apoptotic signals. Here, we tested whether trovafloxacin administration attenuates the neuroinflammatory response and improves outcomes after brain trauma. METHODS: The murine controlled cortical impact (CCI) model was used to determine whether in vivo delivery of trovafloxacin has anti-inflammatory and neuroprotective actions after brain trauma. Locomotor deficit was assessed using the rotarod test. Levels of tissue damage markers and inflammation were measured using western blot, qPCR, and immunofluorescence. In vitro assays were used to evaluate whether trovafloxacin blocks ATP release and cell migration in a chemotactic-stimulated microglia cell line. RESULTS: Trovafloxacin treatment of CCI-injured mice significantly reduced tissue damage markers and improved locomotor deficits. In addition, trovafloxacin treatment significantly reduced mRNA levels of several pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), which correlates with an overall reduction in the accumulation of inflammatory cell types (neutrophils, microglia/macrophages, and astroglia) at the injury zone. To determine whether trovafloxacin exerted these effects by direct action on immune cells, we evaluated its effect on ATP release and cell migration using a chemotactic-stimulated microglial cell line. We found that trovafloxacin significantly inhibited both ATP release and migration of these cells. CONCLUSION: Our results show that trovafloxacin administration has pronounced anti-inflammatory and neuroprotective effects following brain injury. These findings lay the foundation for future studies to directly test a role for Panx1 channels in pathological inflammation following brain trauma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-018-1069-9) contains supplementary material, which is available to authorized users. BioMed Central 2018-02-13 /pmc/articles/PMC5812039/ /pubmed/29439712 http://dx.doi.org/10.1186/s12974-018-1069-9 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Garg, Charu
Seo, Joon Ho
Ramachandran, Jayalakshmi
Loh, Ji Meng
Calderon, Frances
Contreras, Jorge E.
Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice
title Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice
title_full Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice
title_fullStr Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice
title_full_unstemmed Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice
title_short Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice
title_sort trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812039/
https://www.ncbi.nlm.nih.gov/pubmed/29439712
http://dx.doi.org/10.1186/s12974-018-1069-9
work_keys_str_mv AT gargcharu trovafloxacinattenuatesneuroinflammationandimprovesoutcomeaftertraumaticbraininjuryinmice
AT seojoonho trovafloxacinattenuatesneuroinflammationandimprovesoutcomeaftertraumaticbraininjuryinmice
AT ramachandranjayalakshmi trovafloxacinattenuatesneuroinflammationandimprovesoutcomeaftertraumaticbraininjuryinmice
AT lohjimeng trovafloxacinattenuatesneuroinflammationandimprovesoutcomeaftertraumaticbraininjuryinmice
AT calderonfrances trovafloxacinattenuatesneuroinflammationandimprovesoutcomeaftertraumaticbraininjuryinmice
AT contrerasjorgee trovafloxacinattenuatesneuroinflammationandimprovesoutcomeaftertraumaticbraininjuryinmice